Market Trends of Thyroid Function Test Industry
TSH Test is Expected to Hold the Significant Share Over the Forecast Period
TSH testing gained a significant role in thyroid function testing, further facilitating cost-effective disease screening, introducing new definitions of subclinical hypothyroidism or hyperthyroidism, and delivering biochemical treatment targets. TSH (thyroid-stimulating hormone) test measures how much of this hormone is in a patient's blood. The test finds out whether the thyroid gland is working properly or not.
Factors such as an increase in thyroid diseases, the presence of key players, and various research funding opportunities for endocrine research are expected to bolster the studied segment over the forecast period. For instance, as per the Cancer Australia Statistics, 3,981 new cases of thyroid cancer were diagnosed in Australia (1,152 males and 2,829 females) in 2022.
Also, the TSH tests clearly show complications and chances of various thyroid diseases in obese patients. For instance, as per the article published in October 2022 in Frontiers, since the relationship between obesity and thyroid function is complex and bidirectional, the study demonstrated that a large population with obesity established that TSH levels show an upward trend with increasing degree of obesity in females. Leptin levels emerged as the main metabolic determinant of thyroid function parameters in obesity.
Furthermore, launching new diagnostic products for detecting TSH hormones is expected to boost the market growth during the study period. For instance, in November 2021, Bloom Diagnostics launched its Bloom Thyroid Test to help detect hypothyroidism. The single-use kit can test adults for thyroid-stimulating hormone (TSH) to detect thyroid dysfunction. Also, in September 2022, Bloom Diagnostics celebrated opening its first store in Hungary. The opening of this store coincides with the launch of Bloom's commercial activities and its products in Hungary, including the Bloom Lab and the full range of Bloom Tests, namely the Bloom Ferritin, Thyroid, Inflammation, and Kidney Tests. Thus, an increase in strategic activities by the key players is expected to boost segment growth over the forecast period.
Therefore, due to the increase in the prevalence of thyroid cancer, the rise in product launches, and the presence of key players, the studied segment is expected to grow significantly over the forecast period.
North America Anticipated to Hold a Significant Market Share Over the Forecast Period
North America is predicted to lead the thyroid function test market, owing to the high prevalence of thyroid diseases, strategic activities by the key players, and government initiatives and investments for various endocrinology studies. For instance, as per the American Cancer Society estimations, about 43,720 new cases of thyroid cancer are expected to be diagnosed in 2023. Similarly, as per the Canadian Cancer Society, 6,700 Canadians were diagnosed with thyroid cancer in 2022. Thus, due to the region's high incidences of thyroid cancer, the demand for thyroid function tests is expected to increase for its early diagnosis, driving the market.
Factors such as compulsory screening of newborns for congenital hypothyroidism, revolutionary research on thyroid hormone function, cost-effective methods to detect thyroid cancer, and promising research on Graves' disease may lead to improved prognosis and new preventive treatments of thyroid diseases. According to the article updated in July 2021 and published in the National Library of Medicine, the prevalence of hyperthyroidism in the United States is 1.2%, with an incidence of 20/100,000 to 50/100,000. Although GD is a rare disease, it is creating a burden on the healthcare industry in the country, which will encourage the diagnosis and research studies in the market, thereby propelling the market.
Moreover, the launch of new tests for detecting thyroid levels in the body and the adoption of several key strategies are expected to boost the market in the country. For instance, in January 2022, Quest Diagnostics launched Comprehensive Health Profile from QuestDirect, the consumer-initiated testing platform. It is designed to meet the needs of individuals who want more visibility into their health data and access to preventive care at their convenience. Consumers can add sex-appropriate tests, such as PSA and thyroid function screenings, by upgrading from a standard panel to a Men's or Women's panel.
Thus, due to the increase in the prevalence of thyroid cancer, the rise in product launches, and the presence of key players, the studied market is expected to grow significantly in the studied region.
